MS in the Media - 4 October 2019
28 September - 4 October 2019
These are links to news stories about multiple sclerosis from the last week that may be of interest to people affected by MS in the UK. The link beneath each item will take you to the original story.
Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.
To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter or regular email alerts.
Encouraging results from metformin and fasting trails
Treatment with the diabetes drug metformin led to the recovery of damaged myelin in rats, according to research in Cambridge and Australia. Fasting - going without food every other day for six months - also had the same effect. Further research is needed to see if these approaches might slow progression and encourage repair in humans.
Source: Guardian
MS Trust link: Drugs in development
Lanarkshire MS nurses
The new MS nurse team in Lanarkshire is able to reach more people with MS and is providing accessible, responsive and holistic care, according to a report on their first 18 months in post. The MS Trust helped with the recruitment and gave initial funding for one of the posts as part of the specialist nurse programme
Source: Daily Record
MS Trust link: Map of MS services across the UK
MS in the Media
27 Nov 2020 - 00:00
- Depression affects multitasking in MS
- Benefits process in Scotland
- Cancer risks and multiple sclerosis
- Gut immune cells and relapses
MS in the Media
20 Nov 2020 - 00:00
- New study for advanced MS
- Campaign for fair benefits during the pandemic
- Stem cells compared to Lemtrada
- DMD use and finances
David Martin appointed Chair of the Neurological Alliance
18 Nov 2020 - 00:00
The MS Trust is delighted to announce that CEO David Martin, has been voted in as Chair of the Neurological Alliance.
Sign up to our emails
Get the latest news and research sent straight to your inbox. Find out first about the latest developments in MS treatments, plus updates on the work of the MS Trust.
Share
